Navigation Links
DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology

ient compliance. In addition, by combining rapid release and extended release characteristics, DuoCort's new tablet also delivers a more physiological dose of hydrocortisone, better mimicking the body's natural cortisol serum profile.

About adrenal insufficiency

Recent research on adrenal insufficiency patients taking currently available glucocorticoid replacement therapy demonstrates reduced bone density and unfavourable cardiovascular risk profiles. Recent data also suggest an almost 3-fold increased mortality. Chronic adrenal insufficiency is a rare disease that affects at least 125,000 patients in the European Union.

About DuoCort AB

DuoCort is a drug development company focussed on improving glucocorticoid therapy in several areas of medical need. DuoCort was founded in 2003 by PULS, an early-stage life sciences investment and business development group (www.pulsinvest.se). www.duocort.com

This information was brought to you by Cision http://newsroom.cision.com

Contact

DuoCort
Greg Batcheller, CEO, +46 73 391 9608


'"/>




Page: 1 2

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/28/2014)... Calif. , July 28, 2014  Isis Pharmaceuticals, ... webcast:What:Isis Pharmaceuticals, Second Quarter 2014 Financial Results and Highlights ... 7:30 a.m. PTWhere: www.isispharm.com How:Live on the Internet. ... are unable to participate during the live event, a ... limited time at www.isispharm.com . ABOUT ...
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma Corp. ... will report its second quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... DIA and the National Pharmaceutical Council (NPC) ... User,s Guide  Conference on March 14-15 at the ... will focus on the continued push for increased ... applied within health technology assessments, research planning and ...
... 2012 PhotoVoltaic Solar Cells, Inc. (OTCBB: PVSO) ... February 27, 2012, it completed a share exchange ... focused on developing and commercializing proprietary clinical diagnostic ... as well as companion therapeutics to prevent systemic ...
Cached Medicine Technology:DIA and National Pharmaceutical Council Will Host Two-Day Conference on Comparative Effectiveness Research 2PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 2PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 3PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 4
(Date:7/28/2014)... patients with one of the UK,s most common respiratory ... obstructive pulmonary disease (COPD) is the name for a ... long-term damage to the lungs. Often linked to ... all hospital admissions in the UK, with a high ... are discharged. , A team of researchers, ...
(Date:7/28/2014)... Drorit Silverman, a professional bodybuilder and chiropractor ... investment capital through her crowd funding camping to tap ... States. , According to a statement released by Drorit ... a great window of opportunity for investors like her ... to this, Silverman looks at the 24/7 fitness concept ...
(Date:7/28/2014)... 28, 2014) -- Researchers from The University of Texas Health ... other institutions have identified a combination of pills that cures ... the drugs sofosbuvir and simeprevir, with or without ribavirin, cured ... tolerated by patients, according to the study published today in ... in the U.S. , Eric Lawitz, M.D., clinical professor ...
(Date:7/28/2014)... The North America Carotenoids & Antioxidants Market report ... America with analysis and forecast of revenue. This market is ... $812.7 million by 2018, at a CAGR of 7.1% from ... North America Carotenoids & Antioxidants Market report to get an ... glimpse of the segmentation in the market, and is supported ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The Oneida ... and an incredible field of accompanying PGA TOUR players ... and golf analyst Notah Begay III for the seventh ... Turning Stone Resort Casino ’s Atunyote® Golf Club ... will include Woods, Jason Dufner, Jimmy Walker, Jonas Blixt, ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 3Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 5
... DALLAS and PLANO, Texas, March 1 Skin damage. If,you ... about you -- about,your time as a smoker (lip lines), ... age spots), or perhaps you,re,seeing a little more of Mom ... Yes, part of what you,re seeing is normal skin aging, ...
... The California,Academy of Physician Assistants (CAPA) announced that physician ... Speaker of the,California State Assembly. Bass, a member of ... former faculty member at the,University of Southern California School ... Assembly in 2004., As a physician assistant (PA), ...
... 29, 2008 A new study led by researchers at ... that can enhance the function of a protein that is ... protein, called AML1, plays a critical role in the development ... and immune cells. The findings are published in the March ...
... to be unveiled at the 2008 Orthopedic Research ... Society meeting in San Francisco, ... collaboration with RUSH University in Chicago, announces significant,findings that wear ... accelerated aging. The study, "The Effect,of Accelerated Aging on the ...
... Separate Medical ... Businesses, BATESVILLE, Ind., Feb. 29 Hillenbrand,Industries, Inc. (NYSE: ... a cash tender offer to purchase any and all of ... of which $250,million in aggregate principal amount was outstanding as ...
... small striped fish is helping scientists understand what makes people ... this case, its not the fishs ears that are of ... of the journal PLoS Genetics, researchers at the University of ... zebrafishs lateral linethe faint line running down each side of ...
Cached Medicine News:Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 2Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 3Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 4Health News:Physician Assistant Karen Bass Elected Speaker Elect of California State Assembly 2Health News:Novel mechanism found that may boost impaired function of leukemia protein 2Health News:Pioneer(R) Surgical Technology, Inc. Continues to Prove Science Behind PEEK-on-PEEK(TM) Technology for Motion Preservation Devices 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 2Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 3
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... features: Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: